SANTA CLARA, Calif.– HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office. The innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.
The global wearables medical device market is estimated to reach $196B by 2030 and encompasses a wide variety of capabilities, including diagnostic monitoring such as heart rate and some cardiac arrhythmias, blood pressure, glucose, respiratory, and sleep activity, among others. Currently available wearables are not capable of providing a 12-lead ECG for heart attack detection, complex arrhythmia monitoring or other cardiac disorders. With cutting edge 12-lead ECG based on 3D vector ECG technology built into a smartwatch, HeartBeam’s latest patent further expands on the Company’s anytime, anywhere capabilities.
“The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “This patent may prove to be one of the most valuable patents in our rich and growing patent portfolio and, together with our 12-lead ECG patch patent, I believe, will have a disruptive effect on these existing multi-billion dollar fast-growing markets,” concluded Dr. Vajdic.
While HeartBeam is presently focused on the development, clinical and regulatory activities for the HeartBeam AIMI™ and AIMIGo™ systems, the Company is committed to continue advancing the full potential inherent in its cutting edge 12-lead 3D vector ECG technology as demonstrated in recently issued and allowed patents with potentially enormous market impacts.
